Bahl & Gaynor Inc. Has $18.51 Million Position in Novartis AG (NVS)
Bahl & Gaynor Inc. reduced its stake in shares of Novartis AG (NYSE:NVS) by 2.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 214,814 shares of the company’s stock after selling 5,569 shares during the period. Bahl & Gaynor Inc.’s holdings in Novartis were worth $18,508,000 at the end of the most recent quarter.
A number of other large investors also recently made changes to their positions in NVS. Stelac Advisory Services LLC bought a new position in shares of Novartis in the 3rd quarter worth about $113,000. Columbia Asset Management bought a new position in shares of Novartis in the 3rd quarter worth about $126,000. Howe & Rusling Inc. raised its position in shares of Novartis by 50.9% in the 3rd quarter. Howe & Rusling Inc. now owns 1,705 shares of the company’s stock worth $147,000 after acquiring an additional 575 shares in the last quarter. WESPAC Advisors SoCal LLC bought a new position in shares of Novartis in the 3rd quarter worth about $152,000. Finally, Quad Cities Investment Group LLC bought a new position in shares of Novartis in the 2nd quarter worth about $139,000. 10.99% of the stock is owned by institutional investors and hedge funds.
NVS stock opened at $89.03 on Thursday. Novartis AG has a 1-year low of $72.30 and a 1-year high of $94.19. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.20 and a quick ratio of 0.96. The stock has a market capitalization of $204.65 billion, a PE ratio of 18.51, a price-to-earnings-growth ratio of 1.95 and a beta of 0.73.
Several research firms have recently weighed in on NVS. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research report on Tuesday, November 6th. Goldman Sachs Group raised Novartis from a “neutral” rating to a “conviction-buy” rating in a research report on Friday, November 16th. Wolfe Research began coverage on Novartis in a research report on Tuesday, October 23rd. They issued an “outperform” rating for the company. Guggenheim began coverage on Novartis in a research report on Monday, October 8th. They issued a “neutral” rating for the company. Finally, Zacks Investment Research raised Novartis from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a research report on Tuesday, September 18th. Eleven analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $84.86.
TRADEMARK VIOLATION WARNING: “Bahl & Gaynor Inc. Has $18.51 Million Position in Novartis AG (NVS)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2018/11/22/bahl-gaynor-inc-has-18-51-million-position-in-novartis-ag-nvs.html.
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
Featured Article: Terms to Better Understand Call Options
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.